40 reports

  • 1.4 Allergy Immunotherapy
  • 3. Allergy Immunotherapy Market Analysis

Global Allergy Immunotherapy Market: Industry Analysis & Outlook (2019- 2023) ##.

  • Allergy Immunotherapy
  • Respiratory Disease
  • World
  • Merck & Co., Inc.
  • Stallergenes Greer plc
  • MARKET SEGMENTATION - ALLERGY IMMUNOTHERAPY
  • ALLERGY IMMUNOTHERAPY MARKET

Allergopharma is one of the leading companies in the field of allergen immunotherapy (AIT).

  • Allergy Immunotherapy
  • Company
  • Market Competition
  • Market Size
  • Torii Pharmaceutical Co., Ltd.
  • ALLERGY IMMUNOTHERAPY MARKET
  • ALLERGY IMMUNOTHERAPY MARKET

Allergopharma is one of the leading companies in the field of allergen immunotherapy (AIT).

  • Allergy Immunotherapy
  • Company
  • Market Competition
  • Market Size
  • Torii Pharmaceutical Co., Ltd.
  • 2.8 Allergy Immunotherapy: An Overview
  • 3.1.4 Global Allergy Immunotherapy Market by Method of Administration

Global Allergy Immunotherapy (AIT) Market (2018-2022 Edition) October 2018 Table of Content ##.

  • Allergy
  • Allergy Immunotherapy
  • World
  • Market Size
  • Allergy Therapeutics plc

Global Allergy Immunotherapy Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025 ##.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • World
  • Market Size

Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024 ## Preface ## Scope and Methodology ##. ## Objectives of the Study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimati

  • Allergy Immunotherapy
  • Medical Biotechnology
  • World
  • Market Size

Allergy Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 Chapter ## Preface ##. ##.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • APAC
  • World
  • Market Size
  • May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
  • R&D Progress

Allergy immunotherapy is aimed at increasing the tolerance to allergens that trigger the symptoms.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Anergis SA
  • MAY 15, 2014: RAGWITEK, AN ALLERGY IMMUNOTHERAPY TABLET FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF RAGWEED ALLERGY, IS NOW AVAILABLE IN CANADA
  • MAY 08, 2013: MERCK ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR INVESTIGATIONAL RAGWEED POLLEN SUBLINGUAL ALLERGY IMMUNOTHERAPY TABLET

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Therapy
  • Biomay AG
  • MAY 15, 2014: RAGWITEK, AN ALLERGY IMMUNOTHERAPY TABLET FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF RAGWEED ALLERGY, IS NOW AVAILABLE IN CANADA
  • MAY 08, 2013: MERCK ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR INVESTIGATIONAL RAGWEED POLLEN SUBLINGUAL ALLERGY IMMUNOTHERAPY TABLET

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Biomay AG
  • STALLERGENES ACQUIRES ALERGO PHARMA, ALLERGEN IMMUNOTHERAPY COMPANY
  • STALLERGENES ENTERS INTO DISTRIBUTION AGREEMENT WITH GREER LABS FOR ORALAIR

Currently there are no FDA approved oral allergy immunotherapy treatments.

  • Allergy Immunotherapy
  • United States
  • Company
  • Company Financials
  • Stallergenes Greer plc
  • 11.1 BIBLIOGRAPHY
  • ALLERGEN FOR CAT ALLERGY

ASIT CAN CONTAIN EITHER ONE ALLERGEN OR MULTIPLE ALLERGENS.

  • Allergy Immunotherapy
  • Japan
  • United States
  • Demand
  • Torii Pharmaceutical Co., Ltd.
  • Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets
  • ALK-ABELLO EXPANDS PARTNERSHIP WITH ABBOTT LABS

Grazax is the world' s first and only registered disease-modifying allergy immunotherapy tablet.

  • Allergy Immunotherapy
  • Europe
  • Company Financials
  • Supply
  • ALK-Abelló Group
  • recent US government shutdown.
  • Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • Product Initiative

Global Allergy Immunotherapy Market Analysis & Trends - Product Type(Sublingual immunotherapy drops, Subcutaneous immunotherapy and Sublingual immunotherapy tablets), Application - Forecast to 2025 ## Market Outline ##. ## Research Methodology ##. ##. ## Research Approach &

  • Allergy Immunotherapy
  • Medical Biotechnology
  • United States
  • Forecast
  • Market Size
  • PVX-108 - DRUG PROFILE
  • PVX-108 - DRUG PROFILE

In this study mice were immunised with one of three vaccines containing either a mixture of allergens found in whole extract of roasted peanut or with just one single, purified peanut allergen (" Ara h ##" or " Ara h ##" ).

  • Allergy
  • Allergy Immunotherapy
  • United States
  • Product Initiative
  • Aimmune Therapeutics, Inc.
  • Sep 16, 2019: Intrommune Therapeutics supports outcome of FDA Allergenic Product Advisory Committee Vote
  • Nov 07, 2019: POISED study supports risk of cessation of oral immunotherapy for peanut allergy; PACE study indicates safer peanut allergy treatment approaches are needed

OMIT enables consistent delivery of allergy immunotherapy while a user brushes their teeth.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Aimmune Therapeutics, Inc.
  • ALK-ABELLÓ AS - PRODUCTS AND STRATEGIES
  • STALLERGENES GREER PLC - SEGMENT

Allergopharma is one of the leading companies in the field of allergen immunotherapy (AIT).

  • Allergy Immunotherapy
  • Company
  • Market Segment
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
  • Zhejiang I-Biological Technology Co Ltd

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy Immunotherapy
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

Allergen immunotherapy involves administering gradually increasing amounts of an allergen to a patient over several months.

  • Allergy Drug
  • Allergy Immunotherapy
  • Ophthalmic Solution
  • Pharmaceutical
  • Product Initiative
  • Clinical Trial profile. 54 Trial Title

Desensitizing someone to their allergens with oral immunotherapy takes six months to a year, and can cause allergic reactions along the way.

  • Allergy Immunotherapy
  • Clinical Trial
  • Medical Biotechnology
  • World
  • Product Initiative
  • House Dust Mite Allergy - Product Development Milestones
  • HOUSE DUST MITE (DERMATOPHAGOIDES FARINAE) ALLERGEN EXTRACT - DRUG PROFILE

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 107 Trial Title

The prominent features of this report are - ##.

  • Allergy
  • Allergy Immunotherapy
  • Clinical Trial
  • Medical Biotechnology
  • Allergy Therapeutics plc
  • recent US government shutdown.
  • recent US government shutdown.

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • World
  • Product Initiative
  • STG-120 - DRUG PROFILE
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE

About Sublingual Allergy Immunotherapy (SLIT)-Tablets Allergy immunotherapy, or AIT, treats the underlying cause of environmental allergies using a person' s own immune system.

  • Allergy Drug
  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • Glenmark Pharmaceuticals Ltd.
  • Official Title
  • Official Title

Part ## - Proteomics Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy Immunotherapy
  • Blood Supply
  • Pharmaceutical
  • World
  • Product Initiative
  • 05/29/2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
  • Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

The partnership enables Ergomed and Allergy Therapeutics to develop oral allergy immunotherapies.

  • Allergy Immunotherapy
  • Europe
  • United States
  • Company Financials
  • Allergy Therapeutics plc
  • Clinical Trial profile. 965 Trial Title
  • Clinical Trial profile. 266 Trial Title

Part ## - Proteomics Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy Immunotherapy
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World
  • Clinical Trial profile. 87 Trial Title
  • LATEST CLINICAL TRIALS NEWS ON HOUSE DUST MITE ALLERGY

Manuel Llobet, Chief Executive Officer, commented: " We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company.

  • Allergy Immunotherapy
  • Hospital
  • Medical Biotechnology
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Allergy Immunotherapy
  • Hospital
  • OTC
  • World
  • Product Initiative